Indegene working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
90.10×90.10×89.95×91.33×
2.52×2.29×1.44×2.19×
0.88×0.88×0.97×1.02×
1.62×1.62×1.09×1.51×
1.05×1.05×0.83×1.00×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹593.45

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,272 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Receivable Days (DSO)91.3389.9590.1090.10
Working Capital Turnover2.191.442.292.52
Asset Turnover1.020.970.880.88
Cash Conversion (CFO/Net Income)1.511.091.621.62
CFO/EBITDA1.000.831.051.05
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.